Idiopathic Pulmonary Fibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Treatment Outlook | FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharma, Reviva Pharma, Roche, Vicore Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.

*
Idiopathic Pulmonary Fibrosis companies working in the treatment market are FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment

*
Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.

*
In September 2024, Insilico Medicine has reported encouraging preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug developed using generative AI for the treatment of idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled trial was conducted at 21 sites in China, enrolling 71 patients with IPF. It evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12 weeks of oral ISM001-055. The study included four groups: a placebo group, and three treatment groups receiving 30 mg once daily (QD), 30 mg twice daily (BID), and 60 mg QD.

*
In July 2024, South Korean biotechnology company Bridge Biotherapeutics has completed enrollment for its Phase II clinical trial of BBT-877, a novel autotaxin inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF).

*
In May 2024, Aileron Therapeutics has announced positive results from the first cohort of its ongoing Phase Ib clinical trial evaluating inhaled LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled, multicenter dose-escalation study includes recently diagnosed IPF patients who have not received anti-fibrotic treatment for at least two months.

*
In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced the initiation of its Phase 2b CORAL clinical trial, which will evaluate three doses of Haduvio Trademark (oral nalbuphine ER) in comparison to a placebo in around 160 idiopathic pulmonary fibrosis (IPF) patients with chronic cough. This Phase 2b trial builds on the success of the Phase 2a CANAL trial, which showed a 75.1% reduction in daytime cough frequency, representing a 52.5% improvement over placebo (p



This release was published on openPR.